Featured Research

from universities, journals, and other organizations

More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy

Date:
December 16, 2004
Source:
University Of Texas M. D. Anderson Cancer Center
Summary:
Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).

SAN DIEGO - Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).

The researchers combined two different monoclonal antibodies, alemtuzumab (Campath-1H) and rituximab (Rituxan) with the chemotherapy drugs cyclophosphamide and fludarabine. The combination is referred to as CFAR. Of 31 currently evaluable patients, 7 (23 percent) achieved complete remission, meaning no evidence of CLL remains, and the amount of leukemia in 11 patients (35 percent) has been reduced by at least half, says William Wierda, M.D., Ph.D., assistant professor of medicine in the Department of Leukemia.

"An overall response rate so far of 55 percent is very encouraging in this heavily pretreated population of patients that had limited treatment options," he says.

This study follows one reported by Wierda at last year's ASH meeting in which 143 less heavily pretreated patients were treated with rituximab, cyclophosphamide and fludarabine. This combination produced a response rate of 72 percent, of which 28 percent of patients achieved complete response remission. This complete remission rate was much higher than groups treated with either chemotherapy alone, or in combination.

Wierda and his group thought about adding alemtuzumab to the combination because of the synergistic activity of FCR and report that fludarabine combined with alemtuzumab had activity in patients that were resistant to both these agents. Alemtuzumab targets CD52, a protein expressed on the surface of leukemia cells. Rituximab, approved for use in follicular non-Hodgkin's lymphoma, targets CD20, also a cell surface protein on leukemia cells.

In the current trial, which is ongoing, patients have not experienced serious toxicity or early death, and Wierda expects the number of responders to increase with continued enrollment of less heavily pretreated patients. About half of the patients treated with CFAR had previously received FCR. "Had these patients been treated again with FCR,the response rate would not have reached that achieved with CFAR," he says.


Story Source:

The above story is based on materials provided by University Of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas M. D. Anderson Cancer Center. "More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy." ScienceDaily. ScienceDaily, 16 December 2004. <www.sciencedaily.com/releases/2004/12/041206205625.htm>.
University Of Texas M. D. Anderson Cancer Center. (2004, December 16). More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2004/12/041206205625.htm
University Of Texas M. D. Anderson Cancer Center. "More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2004/12/041206205625.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins